Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 40-week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4

NCT06269107 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06269107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06269107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 40-week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
February 15, 2024
Completion date
July 8, 2025
Enrollment
485 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes